Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Global Phase-3 study initiation expected in the second half of 2024
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
The facility will accommodate over 1,500 employees
Subscribe To Our Newsletter & Stay Updated
